Paroxysmal nocturnal hemoglobinuria in a patient post COVID-19 virus infection: A case report with literature review.
Mohammed AlbalawiTurki AlwasaidiMohammed AlmohammadiAshraf Ahmad AlzariefGhaleb ElyamanyPublished in: Clinical case reports (2023)
COVID 19 is a serious infection that originated in Wuhan, China and has resulted in worldwide morbidity and mortality. It continues to be a major health concern in 2022, being associated with multiorgan failure. Although the pathophysiology of the disease and its complications are not well understood, it is believed that a cytokine storm, triggered by complement activation may be responsible for the severity and complications of the disease. As of now, there is no definitive treatment available. Hematological changes associated with COVID-19 include lymphopenia, anemia, thrombocytopenia, disseminated intravascular coagulopathy, and thrombosis. Paroxysmal nocturnal hemoglobinuria (PNH), on the other hand, is an acquired clonal hematopoietic stem cell disorder that occurs due to an acquired PIG-A mutation affecting the hematopoietic stem cells. Interestingly, PNH exhibits some clinical and laboratory manifestations like those seen in COVID-19. In this report, we present a rare case of PNH that developed following a COVID-19 infection.
Keyphrases
- coronavirus disease
- sars cov
- stem cells
- rare case
- hematopoietic stem cell
- case report
- blood pressure
- atrial fibrillation
- obstructive sleep apnea
- healthcare
- risk factors
- public health
- mental health
- chronic kidney disease
- coronary artery
- pulmonary embolism
- mesenchymal stem cells
- catheter ablation
- squamous cell carcinoma
- radiation therapy
- sleep apnea
- rectal cancer
- locally advanced
- climate change
- risk assessment
- health information
- physical activity
- human health